Document:

Exhibit 10.1

 

July 12, 2004

 

Dr. Ram Sasisekharan

2130 Massachusetts Avenue, 7B

Cambridge, Massachusetts 02139

 

Dear Ram:

 

Reference is made to the Consulting Agreement between Momenta
Pharmaceuticals, Inc. (formerly Mimeon, Inc.) and you dated August 16, 2001, as
amended by letter agreement dated August 1, 2003 (the “Agreement”).  Capitalized terms used herein and not
otherwise defined shall have the meanings given such terms in the Agreement.

 

Pursuant to Section 1 of the Agreement, Company and Consultant hereby
agree to extend the term of the Agreement for one additional year, from August
16, 2004 through August 15, 2005, upon the same terms and conditions,
including, without limitation, those governing compensation, as are set forth
in the Agreement.

 

Consultant
hereby represents that Consultant has not been debarred, and to the best of
Consultant’s knowledge, is not under consideration to be debarred, by the Food
and Drug Administration from working in or providing services to any
pharmaceutical or biotechnology company under the Generic Drug Enforcement Act
of 1992.

 

If the
foregoing is in conformity with your understanding, please sign both copies of
this letter agreement and return one fully-executed copy to me.

 

	
  Very truly yours,

  
	
   

  
	
  /s/ Alan L. Crane

  	
   

  
	
  Alan L. Crane

  
	
  Chief Executive Officer

  
	
   

  
	
  Agreed and accepted:

  
	
   

  
	
  /s/ Ram Sasisekharan

  	
   

  
	
  Ram SasisekharanExhibit 10.2

 

July 2, 2004

 

Dr. Robert S. Langer, Jr.

98 Montvale Road

Newton, Massachusetts 02459

 

Dear Dr. Langer:

 

Reference is made to the
Consulting Agreement dated July 23, 2001 between Momenta Pharmaceuticals, Inc.
(formerly Mimeon, Inc.) and you, as extended by letter agreement dated June 23,
2003 (the “Agreement”).  Capitalized
terms used herein and not otherwise defined shall have the meanings given such
terms in the Agreement.

 

Pursuant to Section 1 of the
Agreement, Company and Consultant hereby agree to extend the term of the
Agreement for one additional year, from July 23, 2004 through July 22, 2005,
upon the same terms and conditions, including, without limitation, those
governing compensation, as are set forth in the Agreement.

 

If the foregoing is in conformity with your
understanding, please sign both copies of this letter agreement and return one
fully-executed copy to me.

 

Very truly yours,

 

	
  /s/ Susan K.
  Whoriskey

  	
   

  
	
  Susan K.
  Whoriskey

  
	
  Vice
  President, Licensing and Business Development

  

 

 

Agreed and accepted:

 

 

	
  /s/ Robert
  S. Langer

  	
   

  
	
  Dr. Robert
  S. LangerExhibit 10.3

 

AMENDMENT

 

This Amendment modifies the
Consulting Agreement between Peter Barton Hutt, Esq., (“Consultant”) and
Momenta Pharmaceuticals, Inc. (“Company”) dated September 18, 2002, as amended
by Letter Agreement dated September 29, 2003 (the “Agreement”).  Capitalized terms used herein and not
otherwise defined shall have the meanings given such terms in the
Agreement.  Consultant and Company hereby
agree as follows:

 

Pursuant to Section 4 of the
Agreement, Company and Consultant hereby agree to extend the Term of the
Agreement for one additional year, from September 18, 2004 through September
17, 2005 (the “Renewal Period”).  Except
as otherwise agreed to in this Amendment, the same terms and conditions as are
set forth in the Agreement shall apply to the rendering of Consulting Services
during the Renewal Period.

 

As compensation for the
Consulting Services during the Renewal Period, Consultant will be granted an
additional non-statutory stock option to purchase 5,000 shares of the Common
Stock of the Company, at an exercise price equal to the fair market value of a
share of Common Stock on the date of grant by the Company, with such option to
vest in 12 equal monthly installments with the first installment vesting one
month from the date of grant.

 

 

Agreed and accepted:

 

	
  /s/ Peter
  Barton Hutt, Esq.

  	
   

  
	
  Peter Barton
  Hutt, Esq.

  

 

Date: September 25, 2004

 

 

Momenta Pharmaceuticals, Inc.

 

	
  By:

  	
  /s/ Susan P.
  Whoriskey, PhD

  	
   

  
	
   

  	
  Susan P.
  Whoriskey, PhD

  
	
   

  	
  Vice
  President, Licensing and Business Development

  

 

Date: October 4, 2004Exhibit 10.4

 

INDUSTRY CONSULTING AGREEMENT

 

THIS AGREEMENT
is made and entered into by and between MOMENTA PHARMACEUTICALS, INC., a
Delaware corporation, having a place of business at 675 West Kendall Street,
Cambridge, Massachusetts  02142 (“Company”)
and Bennett M. Shapiro (“Consultant”) and shall be effective upon the date it
is fully executed by both parties (the “Effective Date”).

 

1.                                       DEFINITIONS

 

“Confidential Information” means any scientific, technical,
trade or business information developed for or possessed by Company (including
that developed by Consultant under the terms of this Agreement) which is
treated by Company as confidential or proprietary, including, without
limitation, information pertaining to  sugars,
heparinases, enzymes, reagents, glycoproteins, proteins, peptides,
glycoconjugates, primers, plasmids, vectors, expression systems, cells, cell
lines, antibodies, organisms, chemical compounds, products, formulations,
technologies, techniques, methodologies, algorithms, notation systems, computer
programs, assay systems, procedures, tests, data, documentation, reports,
sources of supply, know-how, patent positioning, research and development
projects, business plans, business developments, relationships with employees
and consultants, and any other confidential information about or belonging to
Company or Company’s affiliates, suppliers, licensors, licensees, partners,
customers, potential customers or other third parties.

 

Confidential
Information shall not include any information which (a) was known to Consultant
at the time it was disclosed, other than by previous disclosure by Company, as
evidenced by Consultant’s written records at the time of disclosure, (b) is at
the time of disclosure or later becomes publicly known under circumstances
involving no breach of this Agreement, or (c) is lawfully and in good faith
made available to Consultant by a third party who did not derive it, directly
or indirectly, from Company.

 

“Development” means ideas, concepts, discoveries, inventions,
developments, improvements, know-how, trade secrets, methodologies, biological
substances, materials, devices, equipment, algorithms, notation systems,
computer software and hardware, data, documentation and reports (whether or not
protectible under state, federal or foreign patent, trademark, copyright or
similar laws) that are developed or conceived or reduced to practice by
Consultant (a) during the term of this Agreement and (b) (i) in performance of
the consulting services rendered under this Agreement, (ii) by use of Company’s
intellectual property, equipment or facilities or (iii) otherwise at Company’s
expense.

 

 

2.                                       SERVICES

 

2.1  For the term listed on
Attachment A, Company hereby retains Consultant and Consultant hereby agrees to
perform the consulting services listed on Attachment A in exchange for the
compensation listed on Attachment A.  On
the last day of each calendar month, Consultant shall invoice Company for any
expenses incurred during such calendar month in respect of this Agreement.  Payments shall be due within thirty days from
Company’s receipt of each invoice from Consultant.

 

2.2  Consultant represents that
it is under no contractual or other obligation or restriction which is
inconsistent with Consultant’s execution of this Agreement or the performance
of the consulting services contemplated by this Agreement.  During the term of this Agreement, Consultant
will not enter into any agreement, either written or oral, in conflict with
Consultant’s obligations under this Agreement. 
Consultant will arrange to provide the consulting services contemplated
by this Agreement in such manner and at such times that the rendering of the
consulting services under this Agreement will not conflict with Consultant’s
responsibilities under any other agreement, arrangement or understanding or
pursuant to any employment relationship Consultant has at any time with any
third party.

 

2.3 Consultant represents that the performance of the consulting
services contemplated by this Agreement does not and will not breach any
agreement which obligates Consultant to keep in confidence any confidential or
proprietary information of any third party or to refrain from competing with
the business of any third party.

 

2.4  In performing the consulting
services contemplated by this Agreement, Consultant agrees to comply with all
business conduct, regulatory and health and safety guidelines or regulations
established by Company or any governmental authority with respect to the
business of the Company.

 

2.5  Consultant represents that
Consultant has not been debarred, and to the best of Consultant’s knowledge, is
not under consideration to be debarred, by the Food and Drug Administration
from working in or providing services to any pharmaceutical or biotechnology
company under the Generic Drug Enforcement Act of 1992.

 

3.                                       DEVELOPMENTS

 

3.1  All Developments shall be “works
made for hire” and the exclusive property of Company.  Consultant shall promptly and fully disclose
to Company all Developments.  Consultant
shall keep and maintain complete records of all

 

2

 

Developments
and of all work carried out by Consultant under the terms of this
Agreement.  These records shall also be “works
made for hire” and the exclusive property of Company.  Consultant may keep one copy of these records
in Consultant’s files solely for reference purposes.  Consultant hereby assigns to Company all of
Consultant’s right, title and interest in and to any and all Developments.  During and after the term of this Agreement,
Consultant will cooperate fully in obtaining patent and other proprietary
protection for any and all Developments, all in the name of the Company and at
Company’s cost and expense, and, without limitation, shall execute and deliver
all requested applications, assignments and other documents, and take such
other measures as Company shall reasonably request, in order to perfect and
enforce Company’s rights in any and all Developments.  Consultant hereby appoints Company its
attorney-in-fact to execute and deliver any such documents on behalf of
Consultant in the event Consultant shall fail to do so.

 

3.2  Unless agreed to by Company
and covered by an appropriate agreement concerning inventions between the third
party and Company, Consultant shall not 
use any third party intellectual property or facilities in performing
the consulting services contemplated by this Agreement or engage in any other
activities that would result in a third party having an ownership interest in
any Developments.

 

4.                                       CONFIDENTIALITY

 

During the term of this Agreement and thereafter, Consultant shall not
directly or indirectly publish, disseminate or otherwise disclose, use for
Consultant’s own benefit or for the benefit of a third party, or deliver or
make available to any third party any Confidential Information, other than in
furtherance of the purposes of this Agreement and only then with the prior
written consent of Company. 
Notwithstanding the foregoing, if required, Consultant may disclose
Confidential Information to a governmental authority or by order of a court of
competent jurisdiction, provided that such disclosure is subject to all
applicable governmental or judicial protection available for like material and
reasonable advance notice is given to Company. 
During the term of this Agreement and thereafter, Consultant shall
exercise all commercially reasonable precautions to physically protect the
integrity and confidentiality of the Confidential Information and shall not
remove any Confidential Information from the premises of the Company, except to
the extent necessary to fulfill the consulting services contemplated by this
Agreement and then only with the prior oral or written consent of the Company.

 

5.                                       EXPIRATION
AND TERMINATION

 

5.1  This Agreement shall continue
for the term listed on Attachment A unless sooner terminated by written
agreement of both parties or pursuant to the terms of this Section 5.

 

3

 

5.2  Either party may terminate
this Agreement at any time without cause upon not less than thirty days prior
written notice to the other party.

 

5.3  Company may immediately
terminate this Agreement at any time upon written notice to Consultant (a) in
the event of a breach of this Agreement by Consultant which cannot be cured
(e.g., a breach of Section 4), (b) in the case of a material and intentional
misappropriation or destruction of Company’s funds, properties or assets or (c)
a conviction of a crime involving moral turpitude or constituting a felony or
an entering of a plea of nolo contendere to the same.  In addition, Company may terminate this
Agreement for other cause at any time upon fifteen days prior written notice to
Consultant.  Other cause shall mean (x) a
material breach by Consultant of this Agreement where such breach can be cured
and is not remedied within such fifteen day period, (y) the physical or mental
inability of Consultant to perform the consulting services contemplated under
this Agreement or (z) the unsatisfactory performance of the consulting services
contemplated under this Agreement which unsatisfactory performance is not
remedied within such fifteen day period.

 

5.4  Upon termination, neither
Company nor Consultant shall have any further obligations under this Agreement
except that the liabilities accrued through the date of termination and the
obligations which by their terms survive termination including, without
limitation, the applicable confidentiality provisions of this Agreement, shall
survive termination.  Upon termination, Consultant
shall return to Company all Confidential Information.

 

6.                                       MISCELLANEOUS

 

6.1  All consulting services
contemplated under this Agreement shall be rendered by Consultant as an
independent contractor and this Agreement shall not create an employer-employee
relationship between Company and Consultant. 
Consultant shall have no rights to receive any employee benefits, such
as health and accident insurance, sick leave or vacation which are accorded to
employees of Company.  Consultant shall
not in any way represent Consultant to be an employee, partner, joint venturer,
agent or officer of Company.

 

6.2  Consultant shall pay all
required taxes on Consultant’s income under this Agreement.  Consultant shall provide Company with
Consultant’s taxpayer identification number. 
Failure to furnish such information may result in withholding of
payments to Consultant in accordance with regulations of the Internal Revenue
Service.

 

6.3  All formal notices from one
party to the other shall be in writing and shall be given by addressing the
same to the other at the address or facsimile number set forth in this
Agreement or at such other address or facsimile number as either may

 

4

 

specify in
writing to the other.  Such notices to
Company shall be marked “Attention: 
Chief Executive Officer”.  All
such notices shall become effective when (a) deposited in the mail with proper
postage for first class certified mail, return receipt requested, (b) deposited
with a commercial overnight courier, (c) hand delivered or (d) promptly
confirmed by mail, commercial courier or hand delivery when dispatched by
facsimile.

 

6.4  This Agreement is a personal
services agreement.  The rights and
obligations under this Agreement may not be assigned or transferred by either
party without the prior written consent of the other party, except that Company
may assign this Agreement to an affiliated company or in connection with the
merger, consolidation, sale or transfer of all or substantially all of the
business to which this Agreement relates.

 

6.5  This Agreement constitutes
the entire agreement of the parties with regard to its subject matter and
supersedes all previous oral or written representations, agreements and
understandings between Company and Consultant. 
This Agreement may be changed only by a writing signed by both parties.

 

6.6  In the event that any one or
more provisions of this Agreement shall, for any reason, be held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other provision of this Agreement, and
all other provisions shall remain in full force and effect.   If any of the provisions are held to be
excessively broad, any such provision shall be reformed and construed by
limiting and reducing it so as to be enforceable to the maximum extent
permitted by law.

 

6.7  This Agreement shall in all
events and for all purposes be governed by and construed in accordance with the
law of the Commonwealth of Massachusetts, without regard to any choice of law
principle that would dictate the application of the law of another
jurisdiction.

 

 

	
   

  	
  MOMENTA
  PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Alan L.
  Crane

  	
   

  
	
   

  	
  Print Name:  Alan L. Crane

  
	
   

  	
  Title: Chief
  Executive Officer

  
	
   

  	
  Date:
  [illegible]

  
	
   

  	
  Facsimile:
  (617) 491-9701

  

 

5

 

	
   

  	
  CONSULTANT:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Bennett
  M. Shapiro

  	
   

  
	
   

  	
  Print Name:
  Bennett M. Shapiro

  
	
   

  	
   

  
	
   

  	
  Date:  [illegible]

  
	
   

  	
   

  
	
   

  	
  Address:

  	
  532
  LaGuardia Place, Suite 524

  
	
   

  	
   

  	
  New York, NY
  10012

  
	
   

  	
   

  
	
   

  	
  Facsimile:
  (215) 862-1465

  
				

 

6

 

ATTACHMENT A

 

1.  Services:

 

Consultant
shall provide general advice and guidance on a range of process development and
other matters related to Momenta’s research and development efforts.

 

Consultant
will be available for consultation on a schedule and at such places as are
determined by mutual arrangement between Company’s Alan L. Crane, to whom
Consultant will report during the term of the Agreement, and Consultant.  In addition, Consultant will be available for
a reasonable number of telephone and/or written consultations.

 

2.  Compensation and Expenses:

 

As full
compensation for the consulting services rendered under this Agreement, Company
shall grant Consultant, under Company’s 2004 Stock Incentive Plan and standard
form of Non-Statutory Option Agreement, a non-statutory option to purchase, at
fair market value on the date of grant, 10,000 shares of the common stock of
Company.  Subject to any non-renewal or
earlier termination of this Agreement, the 10,000 shares shall vest over a
one-year period in 12 equal monthly installments, with the first installment
vesting one month from the date of grant.

 

Company will
reimburse Consultant for all reasonable travel and other expenses incurred by
Consultant in rendering the consulting services, provided that such expenses
are agreed upon in writing in advance and when confirmed by appropriate written
expense statements and other supporting documentation.

 

3.  Term:

 

The Agreement
will be for an initial term of one year commencing on the Effective Date and
may be extended for additional periods by mutual written consent.

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]